Barclays lowered the firm’s price target on LifeStance to $6 from $8 and keeps an Underweight rating on the shares. The company’s Q2 print that featured a headline beat and more moderated fiscal 2024 guidance raise versus the revenue and EBITDA upside in the quarter, the analyst tells investors in a research note. The firm says LifeStance shares continue to trade at a meaningful premium to peers.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST: